Cumberland Seeks Drug Partners After Selling Its Commercial Business For $100 Million

Management projects more than five years of operating funding as Cumberland prepares an FDA application for its lead rare-disease treatment.

Share
Cumberland Seeks Drug Partners After Selling Its Commercial Business For $100 Million

Cumberland Pharmaceuticals, which develops medicines for rare diseases, plans to seek partners to commercialize its experimental drugs, Chief Executive Officer A.J. Kazimi said on the company's earnings call Tuesday, following the sale of its commercial business for $100 million. The company's accompanying results release put quarter-end cash at $80.6 million, compared with $11.4 million at the end of 2025.

Cash Replaces The Commercial Brands

Apotex Health took Cumberland's commercial products and organization into its U.S. branded business when the sale closed on July 1. Cumberland now directs its resources toward clinical development rather than selling its former prescription-drug brands.

Kazimi described the partnering initiative as a search for “alternatives for the commercialization of our new product candidates.” Cumberland intends to evaluate potential partners and different transaction structures, using its corporate development team alongside investment banking advisers.

Cumberland has cash to operate “for over five years”, John Hamm said. He estimated that the transaction would provide $108 million in net funding, including another $11 million due within 12 months of closing and taxes of less than $1 million.

Cumberland paid a $1.50-per-share special dividend during the third quarter, totaling $22 million. It also repaid its $5.2 million bank credit line this summer and carries no debt. Quarter-end liabilities were $41.6 million, down from $52.3 million at the end of 2025, while shareholders' equity rose to $72.5 million from about $25 million.

Third-quarter net income was $77.8 million, including the gain from selling the commercial assets. Interest income reached $0.8 million. Hamm said Cumberland has begun implementing its authorized share repurchase initiative; several directors also entered trading plans intended to increase their holdings this quarter.

Duchenne Application Leads The Pipeline

Cumberland plans to seek FDA approval for ifetroban to treat heart disease associated with Duchenne muscular dystrophy, a fatal genetic disease affecting skeletal, heart and lung muscles. No approved treatment specifically targets its associated heart disease, the leading cause of death in these patients.

The FDA granted rolling review, allowing Cumberland to submit completed application sections before finishing the entire package. Kazimi said the submission will include additional analyses and longer-term patient data requested at the pre-submission meeting this fall.

In the mid-stage trial, the high-dose group showed a statistically significant 5.4-percentage-point improvement in left ventricular ejection fraction—a measure of the heart's pumping function—against a control combining placebo patients and matched natural-history patients. The application will also include manufacturing information, preclinical research published in the Journal of the American Heart Association and safety data covering more than 1,400 subjects across approximately 30 studies.

Cumberland reported no treatment-related serious adverse events or new safety concerns through up to 36 months of treatment in the trial and its extension. Ifetroban has Orphan Drug, Rare Pediatric Disease and Fast Track designations; the FDA conditionally accepted DYSCORBAN as its brand name.

Other Trials Shape Partnering Options

Todd Anthony, Cumberland's Senior Vice President, Operations and Chief Compliance Officer, said its systemic sclerosis trial was not designed to establish efficacy. The drug was generally well tolerated, and Cumberland plans further biomarker and cardiac-imaging work to help decide whether to continue developing it for that disease.

Enrollment continues in its idiopathic pulmonary fibrosis study after an independent safety review found no new safety concerns requiring changes. Management expects interim efficacy results as the next milestone.

Cumberland is also planning a follow-up cancer-metastasis study with Vanderbilt Health. The completed mid-stage trial met its main safety goal and produced preliminary efficacy signals, including fewer metastatic recurrences and metastasis-related deaths than placebo; the next study is expected to focus on selected cancer types.

Cumberland retained majority ownership of Cumberland Emerging Technologies, founded with Vanderbilt University and Launch Tennessee to help bring academic biomedical discoveries to market.

Kazimi said Cumberland expects to announce when its rolling Duchenne FDA submission begins and when it is complete. Approval remains pending.

Sources

More on Cumberland Pharmaceuticals

All Cumberland Pharmaceuticals (CPIX) coverage →